Sone-333

A major limitation of current KRAS G12C inhibitors is the rapid emergence of resistance. SONE-333 was specifically engineered to address three primary resistance pathways:

If you could provide more context about what "SONE-333" refers to, I'd be happy to help you create more targeted and relevant content. SONE-333

Based on the standard nomenclature used in modern medical and pharmacological literature, refers to a novel, highly selective, small-molecule inhibitor targeting the KRAS G12C mutation . This mutation is a primary oncogenic driver in non-small cell lung cancer (NSCLC) and, to a lesser extent, colorectal and pancreatic cancers. A major limitation of current KRAS G12C inhibitors